Helen Ljungdahl Round is President and CEO of Acarix. Acarix AB is a publicly traded company on Nasdaq First North Growth Market, and a leader in AI driven diagnostics for rule-out of coronary artery disease. FDA has granted De Novo clearance for its CADScor®System, and the company is now entering the US market
Prior to Acarix, Helen was CEO of Amnicell, a biotech company. She has extensive global pharmaceutical experience from more than 25 years with Merck & Co, and medical technology experience from GN Hearing. Her experience spans across Corporate Strategy, Data and Analytics, Product Development, Global Marketing, Medical Affairs, Digital Transformation, Business Development, Partnerships and Alliance Management.
Helen also serves as Vice Chair of the Board of Directors, Pearl S. Buck International. She is advisor to SonicCloud, a California-based software technology company and she previously served on the Corporate Board of the International Osteoporosis Foundation.
Helen holds a BSc in Economics from Uppsala University, Sweden, and an MBA from the American Graduate School of International Management, AZ, USA.
